# Jorge Conde
Jorge Conde is a venture capital investor and a general partner on the Bio + Health team at [Andreessen Horowitz](https://www.edgepedia.org/andreessen-horowitz), where he invests in life sciences and healthcare companies spanning therapeutics, diagnostics, tools, and software.[1](https://a16z.com/author/jorge-conde/) He joined the firm in 2017 after roughly fifteen years in genomics as an entrepreneur and executive, and his board seats have included Asimov, Dyno Therapeutics, EQRx, IDRx, and Komodo Health.[2](https://techcrunch.com/2017/06/21/andreessen-horowitz-gets-a-new-general-partner-in-jorge-conde/) • [1](https://a16z.com/author/jorge-conde/)
| | |
|---|---|
| **Current role** | General Partner, Bio + Health, Andreessen Horowitz (announced June 2017; start September 2017)[1](https://a16z.com/author/jorge-conde/) • [2](https://techcrunch.com/2017/06/21/andreessen-horowitz-gets-a-new-general-partner-in-jorge-conde/) |
| **Prior roles** | Chief Strategy Officer, CFO, and Chief Product Officer at Syros; co-founder and CEO of Knome; earlier roles at MedImmune and Morgan Stanley[1](https://a16z.com/author/jorge-conde/) |
| **Education** | MBA, Harvard Business School; MS, Harvard-MIT Division of Health Sciences and Technology; BA in biology, Johns Hopkins University[1](https://a16z.com/author/jorge-conde/) |
| **Current boards** | Asimov, Cartography, Dyno, Earli, Komodo Health, Octant Bio[1](https://a16z.com/author/jorge-conde/) |
| **Exited board seats** | EQRx (acquired by Revolution Medicines), IDRx (acquired by GSK), Tmunity (acquired by Gilead/Kite)[1](https://a16z.com/author/jorge-conde/) |
| **Funds** | Co-investor in the $200M AH Bio Fund (2015)[2](https://techcrunch.com/2017/06/21/andreessen-horowitz-gets-a-new-general-partner-in-jorge-conde/); announced a new $700M a16z Bio + Health fund in January 2026[3](https://www.linkedin.com/posts/jorge-conde-4099225_announcing-our-newest-a16z-bio-health-fund-activity-7415411162303016960-SZep) |
## Education and early career
Conde trained in both science and business: he holds a BA in biology from [Johns Hopkins University](https://www.edgepedia.org/johns-hopkins-university), an MS from the Harvard-MIT Division of Health Sciences and Technology, and an MBA from [Harvard Business School](https://www.edgepedia.org/harvard-business-school).[1](https://a16z.com/author/jorge-conde/)
His operating career centered on genomics. He co-founded [Knome](https://www.edgepedia.org/knome), a human genome interpretation company, and served as its chief executive officer; Knome was acquired by Tute Genomics in 2015, with terms undisclosed.[1](https://a16z.com/author/jorge-conde/) • [2](https://techcrunch.com/2017/06/21/andreessen-horowitz-gets-a-new-general-partner-in-jorge-conde/) He then held three C-suite roles at [Syros Pharmaceuticals](https://www.edgepedia.org/syros-pharmaceuticals), serving as Chief Strategy Officer, Chief Financial Officer, and Chief Product Officer; Syros went public the year before his move into venture capital.[1](https://a16z.com/author/jorge-conde/) • [2](https://techcrunch.com/2017/06/21/andreessen-horowitz-gets-a-new-general-partner-in-jorge-conde/) Earlier in his career he worked in marketing and operations at MedImmune, the biologics developer, and as a biotechnology investment banker at [Morgan Stanley](https://www.edgepedia.org/morgan-stanley).[1](https://a16z.com/author/jorge-conde/)
## Role at Andreessen Horowitz
Andreessen Horowitz announced Conde's hire as a general partner in June 2017, with an official start in September 2017, as part of an expanded push into healthcare.[2](https://techcrunch.com/2017/06/21/andreessen-horowitz-gets-a-new-general-partner-in-jorge-conde/) He joined to co-invest alongside [Vijay Pande](https://www.edgepedia.org/vijay-s-pande) out of the $200 million AH Bio Fund the firm raised in 2015; at the time of his arrival that fund had made 11 investments across 10 startups.[2](https://techcrunch.com/2017/06/21/andreessen-horowitz-gets-a-new-general-partner-in-jorge-conde/)
His investing focus, as he and the firm describe it, is the cross-section of biology, computer science, and engineering: companies using software and engineering approaches to build better medicines and to improve how medicine is practiced.[4](https://www.octant.bio/team/jorge-conde) • [3](https://www.linkedin.com/posts/jorge-conde-4099225_announcing-our-newest-a16z-bio-health-fund-activity-7415411162303016960-SZep) In January 2026 he announced the firm's newest Bio + Health fund, sized at $700 million, to back founders working on both goals.[3](https://www.linkedin.com/posts/jorge-conde-4099225_announcing-our-newest-a16z-bio-health-fund-activity-7415411162303016960-SZep)
## Notable investments and exits
His board service has spanned a16z Bio + Health portfolio companies including genetic medicines and synthetic biology companies (Asimov, Dyno, Octant), therapeutics companies (EQRx, IDRx, Tmunity), and healthcare software and data (Komodo Health).[1](https://a16z.com/author/jorge-conde/)
Several of his board seats have ended in acquisitions:
- EQRx was acquired by [Revolution Medicines](https://www.edgepedia.org/revolution-medicines); Conde served on its board through the acquisition.[1](https://a16z.com/author/jorge-conde/)
- IDRx was acquired by GSK, with Conde's board tenure ending in January 2025 at completion of the deal.[1](https://a16z.com/author/jorge-conde/)
- Tmunity was acquired by Gilead/Kite, again with Conde on the board through the transaction.[1](https://a16z.com/author/jorge-conde/)
His current board seats include Asimov, Cartography, Dyno, Earli, Komodo Health, and Octant Bio.[1](https://a16z.com/author/jorge-conde/) An earlier roster on Octant's team page also listed Camp4 and twoXAR, indicating board service that has since rotated off the firm's current listing.[4](https://www.octant.bio/team/jorge-conde)
The financial terms of the EQRx, IDRx, and Tmunity acquisitions, and the returns they produced for Andreessen Horowitz, are not stated in the sources on record.
## Public positions and recognition
Conde leads investments, as he and the firm describe it, at the cross-section of biology, computer science, and engineering.[4](https://www.octant.bio/team/jorge-conde) His January 2026 fund announcement framed the mandate as backing founders making better medicines and making the practice of medicine better.[3](https://www.linkedin.com/posts/jorge-conde-4099225_announcing-our-newest-a16z-bio-health-fund-activity-7415411162303016960-SZep)
No Forbes Midas List ranking or comparable post-2023 recognition appears in the sources on record.
## Recent developments
Two developments mark his record since 2023. The IDRx board seat ended in January 2025 when GSK completed its acquisition of the company.[1](https://a16z.com/author/jorge-conde/) And in January 2026, Conde announced a new $700 million a16z Bio + Health fund, confirming his continuing senior role in the franchise.[3](https://www.linkedin.com/posts/jorge-conde-4099225_announcing-our-newest-a16z-bio-health-fund-activity-7415411162303016960-SZep)
## References
1. [Jorge Conde, General Partner at Andreessen Horowitz](https://a16z.com/author/jorge-conde/)
2. [Andreessen Horowitz gets a new general partner in Jorge Conde, TechCrunch (June 21, 2017)](https://techcrunch.com/2017/06/21/andreessen-horowitz-gets-a-new-general-partner-in-jorge-conde/)
3. [Announcing our newest a16z Bio + Health fund: $700M, Jorge Conde (January 2026)](https://www.linkedin.com/posts/jorge-conde-4099225_announcing-our-newest-a16z-bio-health-fund-activity-7415411162303016960-SZep)
4. [Jorge Conde, Octant team page](https://www.octant.bio/team/jorge-conde)
---
*Topic: Encyclopedia › Society and history › Economics and business › Founders, operators, and investors › Venture and growth investors › Life-science venture and company creation › Healthcare growth and digital investors*
*Initially written Sep 17, 2026 · Edited: Oct 11, 2026; Oct 15, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license